Trial Profile

A Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of CARDAMYST (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT)

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 29 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2026 According to Milestone Pharmaceuticals media release, Sean D. Pokorney, is the Lead Investigator of this study.
17 Apr 2026 New trial record
10 Apr 2026 Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium, according to Milestone Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com